The Science Journal of the Lander College of Arts and Sciences
Abstract
Regenerative medicine has gained significant traction due to its potential to repair or replace damaged tissues and organs, with stem cell therapies emerging as a promising avenue for treating various diseases. While bone marrow-derived MSCs (BM-MSCs) are commonly used in clinical settings, their limitations, such as the invasive extraction procedure and limited proliferation capacity, underscore the need for alternative stem cell sources. Placenta-derived mesenchymal stem cells (PDMSCs) represent a promising solution, offering advantages such as greater proliferative capacity, faster expansion rates, and reduced risk of immune rejection compared to adult stem cells. The placenta is a rich source of MSCs, hematopoietic stem cells, and other progenitor cells. Additionally, placenta-derived cells can be cryopreserved for long-term storage and potential future use, facilitating their availability for regenerative therapies. Based on the evidence presented, private banking may be a viable option for individuals at higher risk of diseases treatable with stem cell therapy. However, for most people, the high cost and low chance of needing these stem cells make private banking an inefficient choice. Instead, considering the lack of ethical concerns surrounding the collecting of placentaderived stem cells, public stem cell banking is recommended as a beneficial alternative for broader access to potentially life-saving treatments.
Recommended Citation
Chaya Nathan. (2025). Is Placenta Stem Cell Banking Worthwhile?. The Science Journal of the Lander College of Arts and Sciences, 18(2), 94-99. Retrieved from https://touroscholar.touro.edu/sjlcas/vol18/iss2/12
